SCHEMBL9904776

SCHEMBL9904776

CC(C)(C)OC(=O)NC1CCN(c2cncc(-c3c[nH]c4ccc(-c5c(F)cccc5F)nc34)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 1/20 0.42
▸ SKP1 P63208 1/20 0.42
▸ SKP2 Q13309 1/20 0.42
▸ PARP1 P09874 3/20 0.39
▸ WNT1 P04628 2/20 0.39
▸ DYRK1A Q13627 2/20 0.39
▸ SUV39H2 Q9H5I1 5/20 0.39
▸ IGF1R P08069 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CNR1 P21554 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ ITGB2 P05107 1/20 0.37
▸ ICAM1 P05362 1/20 0.37
▸ ITGAL P20701 1/20 0.37
▸ MET P08581 1/20 0.37
▸ NPY5R Q15761 1/20 0.36
▸ BTK Q06187 1/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ PIM3 Q86V86 1/20 0.36
▸ PIM2 Q9P1W9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15440574 0.93 CKS1B (0.44) CKS1BSKP1SKP2PARP1WNT1
SCHEMBL9904489 0.81 PIM1 (0.50) PIM1PIM3PIM2
SCHEMBL9904437 0.79 CKS1B (0.37) CKS1BSKP1SKP2SUV39H2CNR1
SCHEMBL9904239 0.77 PIM1 (0.43) PARP1BTKPIM1PIM2
SCHEMBL9904273 0.76 PIM3 (0.45) CKS1BSKP1SKP2SUV39H2PIM1
SCHEMBL9942513 0.73 TYK2 (0.40) CKS1BSKP1SKP2PARP1WNT1
SCHEMBL9904710 0.72 ALOX5AP (0.39) CKS1BSKP1SKP2SUV39H2CNR1
SCHEMBL9904737 0.71 WNT1 (0.39) CKS1BSKP1SKP2WNT1DYRK1A
SCHEMBL8511476 0.70 CKS1B (0.46) CKS1BSKP1SKP2WNT1DYRK1A
SCHEMBL12991183 0.69 CKS1B (0.59) CKS1BSKP1SKP2SUV39H2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 — — US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 — — EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 — — US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 — — EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 CKS1B 342/4885SKP1 176/4885SKP2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback